Correlation of MET and PD-L1 expression in malignant melanoma

Keyphrases

• Melanoma 100%
• Malignant Melanoma 100%
• Programmed Death-ligand 1 Expression 100%
• Programmed Death-ligand 1 (PD-L1) 66%
• Metastatic Melanoma 66%
• Primary mucosal Melanoma 66%
• Primary Cutaneous Melanoma 66%
• Therapeutic Target 33%
• Malignancy 33%
• Tumor 33%
• Relative Expression Level 33%
• Receptor Tyrosine Kinase 33%
• Antitumor Immune Response 33%
• Tumor Metastasis 33%
• Oncogene 33%
• Predictive Biomarker 33%
• Advanced Testing 33%
• Aberrations 33%
• Response to Immunotherapy 33%
• Immunohistochemical Analysis 33%
• Advanced Disease 33%
• Tumor Resistance 33%
• Human Melanoma 33%
• Membrane Receptors 33%
• Human Melanoma Cells 33%
• Primary Lesion 33%
• Tissue Microarray 33%
• Biomarkers of Response 33%
• Hepatocyte Growth Factor Receptor 33%
• Melanocytic Lesions 33%
• Benign Melanocytic Nevi 33%
• Robust Correlation 33%
• MET Expression 33%
• Color Deconvolution 33%
• Evade 33%
• Resistance to Anticancer Therapy 33%
• Metastatic Lesions 33%
• MET Gene Amplification 33%

Medicine and Dentistry

• Programmed Death 1 Ligand 1 100%
• Melanoma 100%
• Neoplasm 40%
• Metastatic Melanoma 40%
• Cutaneous Melanoma 40%
• Mucosal Melanoma 40%
• Disease 20%
• Biological Marker 20%
• Immune Response 20%
• Cancer 20%
• Metastatic Carcinoma 20%
• Proto Oncogene 20%
• Protein Tyrosine Kinase 20%
• Immunohistochemistry 20%
• Tissue Microarray 20%
• Cancer Treatment 20%
• Scatter Factor Receptor 20%
• Melanoma Cell Line 20%
• Gene Amplification 20%
• Tumor Resistance 20%
• Benign Melanocytic Nevus 20%
• Immunotherapy 20%